Medline Inc. Class A Common Stock (MDLN) fair value: what the stock is really worth
We calculate from audited financials what Medline Inc. Class A Common Stock is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Medline Inc. Class A Common Stock for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Sep 17, 2026.
How to read this chart
9‑month range $31.64 – $49.99 · fair‑value band $8.03 – $14.56 · the $31.64 price screens above the $11.65 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Sep 17, 2026.
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and Supply Chain Solutions.
Show more
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and Supply Chain Solutions. The Medline Brand segment procures and manufactures products from three product categories include surgical solutions, front line care, and laboratory and diagnostics. Its front line care offers med-surg products for patient-facing needs, including wound care products, exam gloves, skin care and incontinence products, environment cleaning supplies, textiles, hand sanitizer, durable medical equipment, patient plastics, and decolonization and infection control products. Its surgical solutions provide operating room and perioperative environment product solutions, including surgical procedure trays, drapes and gowns, personal protective equipment, sterile wraps, surgical instruments, surgeon's gloves, procedure kits, and orthopedic implants. Its laboratory and diagnostics offer laboratory and diagnostic product solutions, including point of care testing, analyzers and instrumentation, lab and diagnostic consumables, diagnostic instruments, vital signs monitors, and anatomic pathology and phlebotomy products. It provides its products to domestic and international consumers. The Supply Chain Solutions segment procures and distributes a variety of third-party products from national brands. It provides logistics and supply chain optimization services to domestic and international consumers. It also provides supply chain optimization services, such as consulting engagements, outsourced warehouse and technology management, put-away-ready packaging, third-party logistics, inventory rationalization, and route planning. The company was founded in 1966 and is based in Northfield, Illinois.
Stock analysis
Medline Inc. Class A Common Stock (MDLN) currently trades at $31.64, while our model-based Fair Value estimate is $11.65, implying the stock looks roughly 171.6% overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of $16.36 per share, and 0 of the 26 models we run sit above the $31.64 price.
Bear case: the Asset-Based group reads lowest at $3.24, and 26 of the 26 models stay below the price. Evidence for this calculation is medium.
Scenario range: $8.03 (bear) to $14.56 (bull), the price of $31.64 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Medline Inc. Class A Common Stock reported revenue of $28.4B in FY2025 versus $21.4B in FY2022, a compound +9.9%/yr. Reported net income was $1.2B in FY2025.
Key figures
Market cap $70.3B · P/E ratio 30.2 · P/S ratio 1.23 · EPS (TTM) $1.14 · Dividend yield 1.1% · Net margin 4.1% · Return on equity 6.1% · Return on assets (EBIT) 5.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 51 out of 100 (low confidence).
What moves the price
The share trades about 38% below its 52-week high, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −41% fair-value upside, at −63%, MDLN screens richer than that median.
Fair Value models
Bear $8.03Fair Value $11.65Bull $14.56
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.8245 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.76/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+11.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.9%
’22
’23
’24
’25
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
≈ +69.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+68.7%
Dividend (yield on the price)1.1%
Profit margin 2022 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4% → 8%
⚠ Approximate: the rate leans on 2025, which sits 57% above its own trend.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+1.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+10.4%
Yearly sales growth analysts expect, extended to five years.
News mood ⓘNews mood, the average tone of recent news (97 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
Compare Medline Inc. Class A Common Stock with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 200 stocks
Beats the industry median on 4/13 measures
Overall it trails its industry peers.
Valuation
Quality Score57 · Above median
Fair Value upside−18% · Below median
Profitability
Return on equity (TTM)6% · Below median
Return on assets4% · Above median
Net margin (TTM)3% · Below median
Operating margin (TTM)5% · Below median
Growth and dividend
Revenue growth11% · Above median
Dividend yield (TTM)1.1% · Below median
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/E (TTM)30.2× · Pricier than median
P/B6.54× · Priciest 25%
P/S (TTM)2.41× · Cheaper than median
P/FCF40.3× · Priciest 25%
EV/EBITDA22.5× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 15
FUTURE (revenue growth)54· sector 27
PAST (return on equity)24· sector 25
HEALTH (low debt)0· sector 96
DIVIDEND (yield)23· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Medline Inc. Class A Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/MDLN
Frequently asked questions
Is Medline Inc. Class A Common Stock (MDLN) overvalued or undervalued?
As of Sep 17, 2026, our model estimates a fair value of $11.65 versus a price of $31.64, about −63% upside (overvalued).
What is the fair value of MDLN?
Our model-based fair value for Medline Inc. Class A Common Stock is $11.65 (as of Sep 17, 2026), built from audited fundamentals. The current price: $31.64.
What is the quality score of MDLN?
Medline Inc. Class A Common Stock has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medline Inc. Class A Common Stock (MDLN)?
Our model-based price target is the fair value of $11.65 (as of Sep 17, 2026) from 26 valuation models. Cautious scenario $8.03, optimistic scenario $14.56. It is a calculation from audited fundamentals, not an analyst target.
What is the Medline Inc. Class A Common Stock stock forecast for 2026?
Our models put fair value at $11.65, about −63% upside versus a price of $31.64 (overvalued). Cautious scenario $8.03, optimistic scenario $14.56. The calculation is refreshed regularly with new filings.
What is the revenue of Medline Inc. Class A Common Stock (MDLN)?
Medline Inc. Class A Common Stock reported trailing-twelve-month revenue of about $29.1B (latest available figure, as of Sep 17, 2026).
Does Medline Inc. Class A Common Stock pay a dividend?
Medline Inc. Class A Common Stock currently shows a dividend yield of about 1.14% relative to its recent price (as of Sep 17, 2026).
What growth is priced into Medline Inc. Class A Common Stock (MDLN)?
For today's price to be fair in a discounted-cash-flow model, Medline Inc. Class A Common Stock would have to grow free cash flow by +1.4 % per year for five years (discount rate 9.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 3 years revenue grew +9.9 % per year. As of Sep 17, 2026.
What discount rate (WACC) does the fair value of MDLN use?
Our models discount Medline Inc. Class A Common Stock at 9.2 %: a base by market capitalisation (large), country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Medline Inc. Class A Common Stock that is +1.4 % per year a year over ten years, using the same discount rate (9.2 %) and the same formula as our fair value.
How much growth has Medline Inc. Class A Common Stock (MDLN) delivered so far?
Over the past 3 years revenue at Medline Inc. Class A Common Stock grew +9.9 % a year. The price currently implies +1.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Medline Inc. Class A Common Stock (MDLN) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into Medline Inc. Class A Common Stock (+1.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Medline Inc. Class A Common Stock (MDLN)?
The free-cash-flow yield on the price is 6.79 %: that much free cash flow Medline Inc. Class A Common Stock produces per unit of market value. When it exceeds the discount rate of our models (9.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Medline Inc. Class A Common Stock (MDLN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medline Inc. Class A Common Stock it is $11.65 per share (as of Sep 17, 2026), against a price of $31.64. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Medline Inc. Class A Common Stock stock overvalued or undervalued in 2026?
As of Sep 17, 2026, MDLN trades above its calculated fair value: price $31.64, fair value $11.65, a gap of about −63% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MDLN?
No. The price is what the market pays today ($31.64); the fair value is what the company's own numbers justify ($11.65). For Medline Inc. Class A Common Stock the two are $19.99 per share apart. That gap is exactly why we show both numbers side by side.
How much is Medline Inc. Class A Common Stock worth?
The market values Medline Inc. Class A Common Stock at about $70.3B (market capitalisation, as of Sep 17, 2026). Per share that is $31.64; our models calculate a fair value of $11.65 per share.
What do the bullish and bearish scenarios say about MDLN?
Our models span a range for Medline Inc. Class A Common Stock: cautious scenario $8.03, base $11.65, optimistic $14.56 per share (as of Sep 17, 2026, price $31.64). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of MDLN?
Medline Inc. Class A Common Stock trades at a price-to-earnings ratio of 30.2 (as of Sep 17, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $11.65 is built from several models across several years. Other multiples: P/B 6.5, P/S 2.4, EV/EBITDA 22.5.
How solid is the balance sheet of Medline Inc. Class A Common Stock (MDLN)?
Balance-sheet figures for Medline Inc. Class A Common Stock (as of Sep 17, 2026): return on equity 6.1%. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is MDLN from its 52-week high?
Medline Inc. Class A Common Stock trades at $31.64, about 38% below its 52-week high of $50.88 (as of Sep 17, 2026). Distance from the high says nothing about value: that is what the fair value of $11.65 is for.
Which stocks are comparable to Medline Inc. Class A Common Stock?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Alcon Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medline Inc. Class A Common Stock stock attractive at the current price?
The data as of Sep 17, 2026: price $31.64, calculated fair value $11.65 (−63%), Quality Score 57/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MDLN calculated?
We run Medline Inc. Class A Common Stock through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $11.65, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.1 % above its aggregate fair value. Medline Inc. Class A Common Stock itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medline Inc. Class A Common Stock (MDLN)?
The closing price on Sep 18, 2026 was $31.64. Our model-based fair value is $11.65, about −63% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medline Inc. Class A Common Stock right now?
The price sits above even our optimistic bull case ($14.56). The favourable scenario is already priced in. Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($8.03 to $14.56) leaves room in how you read the outcome.
Key figures of Medline Inc. Class A Common Stock
How large is the market capitalisation of Medline Inc. Class A Common Stock (MDLN)?
The market capitalisation of Medline Inc. Class A Common Stock is $70.3B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medline Inc. Class A Common Stock (MDLN)?
The price-to-sales ratio of Medline Inc. Class A Common Stock is 1.23 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Medline Inc. Class A Common Stock (MDLN)?
Earnings per share at Medline Inc. Class A Common Stock are $1.14 (price ÷ EPS = P/E 30.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Medline Inc. Class A Common Stock (MDLN)?
The dividend yield of Medline Inc. Class A Common Stock is 1.1% (payout 31.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Medline Inc. Class A Common Stock (MDLN)?
The net margin of Medline Inc. Class A Common Stock is 4.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Medline Inc. Class A Common Stock (MDLN)?
The return on equity (ROE) of Medline Inc. Class A Common Stock is 6.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Medline Inc. Class A Common Stock (MDLN)?
On an EBIT basis the return on assets of Medline Inc. Class A Common Stock is 5.3% (avg 3y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medline Inc. Class A Common Stock (MDLN)?
The operating margin of Medline Inc. Class A Common Stock is 5.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medline Inc. Class A Common Stock (MDLN)?
Revenue at Medline Inc. Class A Common Stock is growing +10.7% versus a year earlier (3y avg +9.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Medline Inc. Class A Common Stock (MDLN)?
Earnings per share at Medline Inc. Class A Common Stock are growing +12.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Medline Inc. Class A Common Stock (MDLN) carry?
The net debt of Medline Inc. Class A Common Stock is $10.6B (fiscal year 2025, ≈ 6.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Medline Inc. Class A Common Stock in the live analysis
One click puts Medline Inc. Class A Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Some data
Sep 17, 2026